Novo Nordisk Shares Plummet After Failed Heart Drug Trial
Novo Nordisk's stock plummeted by as much as 10% after its cardiovascular drug trial yielded disappointing results. This setback wiped out billions in market value and added to the company's recent challenges.
The Story
Analyzing sources…
Source Diversity
Source Diversity
High (67/100)Sources
European Stocks Trim Monthly Gain as Novo Nordisk and UMG Slump
European shares pared some of their Friday gains as a decline on Novo Nordisk A/S weighed on the market, countering a rally in tech stocks and another round of largely upbeat results.
By Macarena Muñoz and Julien Ponthus
Read full article →Novo Nordisk shares drop 10% after cardiovascular drug trial disappoints
Danish drugmaker has been trying to diversify beyond its blockbuster obesity treatments Wegovy and Ozempic
Read full article →Novo Nordisk shares dive 9% after heart medicine fails trial
Read full article →Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes
The Danish healthcare company’s stock slumped on Friday after it announced the Phase 3 trial failure.
By Nora Redmond
Read full article →Novo Nordisk Wipes Out $30 Billion In Market Value After Failed Heart Drug Trial
Analysts were critical of the Ozempic maker’s failed trial for a new experimental drug.
By Ty Roush, Forbes Staff
Read full article →
